secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059491
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q1 net loss $19.6M; appoints Kemi Olugemo as CMO; cash $138.8M plus $70M PIPE
--------------------------------------------------------------------------------

- Net loss $19.6M in Q1 2024, unchanged from Q1 2023; R&D $13.6M, G&A $7.9M.
- Cash $138.8M at Mar 31, 2024; after $70M April PIPE, pro forma ~$206M; runway into H2 2026.
- Appointed Kemi Olugemo, MD, as Chief Medical Officer; she brings >10 yrs industry experience.
- Regulatory filing for KRRO-110 (RNA editing for AATD) on track for H2 2024; interim data H2 2025.
- $70M PIPE led by Deep Track Capital with Atlas Venture, NEA, and other healthcare investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/0000950170-24-059491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/krro-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer